To date, there is only one federally approved aptamer, the Pegaptanib drug, selected against vascular endothelial growth factor (VEGF) to treat the age-related macular degeneration, although there are more than 10 aptamers under different stages of clinical trials for treatment of coagulation, inflammation, cancer, etc. [54]. This evidence concerns the gene VEGFA and age-related macular degeneration.